Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?
暂无分享,去创建一个
[1] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. , 2017, The New England journal of medicine.
[2] S. Adams,et al. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. , 2016, JAMA oncology.
[3] E. Perez,et al. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Paolo Morandi,et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. , 2016, The Lancet. Oncology.
[5] M. Ellis,et al. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. , 2023, The New England journal of medicine.
[6] L. Pusztai,et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Noah D. Goodman,et al. Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer , 2015, Breast Cancer Research.
[8] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[9] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[10] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[11] F. Penault-Llorca,et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? , 2006, British Journal of Cancer.